Clinical Trial Update: Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the mechanism of action of Ligelizumab (QGE031) in patients with chronic urticaria has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholinergic Urticaria
• Cold Urticaria
• Spontaneous Urticaria

Drugs mentioned

• Ligelizumab (QGE031) (ligelizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria, Cholinergic Urticaria | Phase 1 | Status: TERMINATED